UTMD Trades at a Premium to the Industry: How to Play the Stock?

Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.

Zacks Investment Research • Oct 8, 2026

Utah Medical Products, Inc. Extends Tender Offer

SALT LAKE CITY, UT / ACCESS Newswire / October 5, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The Offer was initially scheduled to expire at 5:00 p.m.

Accesswire • Oct 5, 2026

Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date

SALT LAKE CITY, UT / ACCESS Newswire / September 25, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The conditions of the Offer are explained in detail in the SEC Form TO Offer to Purchase and Letter of Transmittal filed with the SEC at https://www.sec.gov/Archives/edgar/data/706698/000109690626001428/0001096906-26-001428-index.html The Offer is scheduled to expire at 5:00 p.m.

Accesswire • Sep 25, 2026

Utah Medical Products, Inc. Commences Tender Offer

SALT LAKE CITY, UT / ACCESS Newswire / September 24, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The $75.00 per share price represents a 17% premium over the average daily closing price of the stock during the last twelve months, and a 21% premium over the average daily closing price of the stock during the last twenty-four months.

Accesswire • Sep 24, 2026

UTMD Announces Self-Tender for 20% of Its Shares

SALT LAKE CITY, UT / ACCESS Newswire / September 15, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces today that it intends to repurchase at a price of $75.00 per share up to 650,000 of its shares, if tendered and not withdrawn by stockholders on or before October 7, representing approximately 20% of its currently outstanding shares. The offering price is 17% higher than the average daily closing price of UTMD shares trading in the open market during the last twelve months, and 21% higher than the average daily closing price of UTMD shares trading during the last two years.

Accesswire • Sep 15, 2026

Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK

SALT LAKE CITY, UT / ACCESS Newswire / August 31, 2026 / Femcare Ltd. ("Femcare"), a wholly-owned subsidiary of Utah Medical Products, Inc. (Nasdaq:UTMD), announces that it has purchased the entire ordinary share capital of Orion Medical Supplies Ltd ("ORION") of the United Kingdom.

Accesswire • Aug 31, 2026

Utah Medical Products, Inc. Announces Quarterly Dividend

SALT LAKE CITY, UT / ACCESS Newswire / August 4, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on October 5, 2026 to stockholders of record at the close of business on September 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year.

Accesswire • Aug 4, 2026

Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

UTMD's Q2 earnings per share decline 10.1% year over year, while quarterly revenues face pressure from lost customers and slower new business growth.

Zacks Investment Research • Jul 29, 2026

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026

SALT LAKE CITY, UT / ACCESS Newswire / July 23, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) reports second calendar quarter (2Q) and first half (1H) 2026 financial results with a continued decline in overall revenues in comparison to the same time periods in 2025. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Accesswire • Jul 23, 2026

Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs

UTMD reports a year-over-year decline in Q1 earnings per share and sales, pressured by lost distributor business and higher costs, despite improved margins and a strong balance sheet.

Zacks Investment Research • Apr 29, 2026